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Abstract
Background: Longer nephrology care before end-stage renal disease (ESRD) has been linked with better outcomes.
Methods: We investigated whether longer pre-end-stage renal disease (ESRD) nephrology care was associated with lower
mortality at both thepatient and state levels among443 761 incident ESRDpatients identified in theUSAbetween 2006 and 2010.
Results: Overall, 33% of new ESRD patients had received no prior nephrology care, while 28% had received care for >12months.
At the patient level, predictors of >12 months of nephrology care included having health insurance, white race, younger age,
diabetes, hypertension andUS region. Longer pre-ESRDnephrology carewas associatedwith lowerfirst-yearmortality (adjusted
hazard ratio = 0.58 for >12months versus no care; 95% confidence interval 0.57–0.59), higher albumin and hemoglobin, choice of
peritoneal dialysis and native fistula and discussion of transplantation options. Living in a statewith a 10%higher proportion of
patients receiving >12 months of pre-ESRD care was associated with a 9.3% lower relative mortality rate, standardized for case
mix (R2 = 0.47; P < 0.001).
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Conclusions: This study represents the largest cohort of incident ESRD patients to date. Although we did not follow patients
before ESRD onset, our findings, both at the individual patient and state levels, reflect the importance of early nephrology care
among those with chronic kidney disease.
Key words: dialysis, glomerular filtration rate, kidney transplantation, nephrology referral, vascular access
Introduction
In 2012, a total of 114 893 individuals in the USA reached end-
stage renal disease (ESRD) [1]. For those approaching ESRD, clin-
ical practice guidelines cover multiple care domains, such as
optimal management of blood pressure, diabetes and anemia,
as well as preparation for ESRD, including timely vascular access
placement or referral for kidney transplantation [2]. The in-
volvement of a nephrologist throughout the more advanced
stages of chronic kidney disease (CKD), preferably in collabor-
ation with a multidisciplinary team, has been strongly recom-
mended [3]. Earlier referral provides the nephrologist time to
identify and manage reversible conditions, ensure avoidance of
nephrotoxic agents, administer specific therapies, recommend
dietary and lifestyle changes to slow the progression of kidney
decline, manage comorbidities and complications and institute
regular follow-up, education and activation of social support.
Even if progression to ESRD is inevitable, earlier nephrology
care can optimally prepare the patient for renal replacement
therapy, both physically and mentally.
Early studies considering the impact of nephrologist involve-
ment prior to ESRD generally assessed only a fewmonths of care
(e.g. 1–4 months prior to ESRD onset). More recent publications
have considered periods longer than the Kidney Disease Out-
comes Quality Initiative (KDOQI)–recommended minimum of
6 months of pre-ESRD care. Results from the national Choices
for Healthy Outcomes in Caring for ESRD (CHOICE) study sug-
gested that increased nephrologist involvement was associated
with improvements in patient preparation and outcomes [4].
Other studies have indicated that the involvement of a nephrolo-
gist prior to initiating dialysis improves a patient’s readiness for
dialysis [5–7], access to transplant waiting lists [8] and first-year
survival after the start of dialysis [9–15]. These studies reported
on selected populations, with data collected prior to 2008.
We analyzed more recent and nationwide US ESRD data from
2006 through 2010 to explore variations in pre-ESRD nephrology
care among incident ESRD patients and its association withmor-
tality at both the patient and state levels. We hypothesized that a
longer duration of pre-ESRD care would be associated with im-
proved outcomes at, and following, the onset of ESRD. Analyses
were performed at both the usual patient level and the region/
state level, which have implications for policymakers for improv-
ing population health.
Materials and methods
Study design
The U.S. Department of Health and Human Services’ Centers for
Medicare and Medicaid Services (CMS) provides federally mana-
ged health insurance for those with ESRD. Data from the CMS
Medical Evidence Form 2728 are required to be submitted pro-
spectively for all incident ESRD patients in the USA [16]. Ques-
tions added to Form 2728 in 2005 included ‘Prior to ESRD
therapy: was the patient under care of a nephrologist (yes, no,
unknown)? If yes, was the duration 6–12months or >12months?’
An answer of ‘yes’ to the first question but no answer to the
second question was considered to be a duration of <6 months.
Other questions requested information on the type of vascular
access used on first outpatient dialysis, and whether the patient
was informed of transplant options.
All 537 940 incident cases of ESRD occurring between 1 January
2006 and 31 December 2010 with information from Form 2728
were eligible for inclusion in these analyses. Individuals were
excluded if their pre-ESRD nephrology care status was unknown
(n = 69 789; 13%) or if their ESRDwas likely due to acute kidney in-
jury (n= 24 390; 5%; based on the International Classification of
Diseases, Ninth Revision, Clinical Modification codes for primary
cause of ESRD’ 282.60, 282.69, 283.11, 572.4, 580.0, 580.89, 583.4,
583.6, 593.81, 593.83, 646.20, 866.0). The final dataset included
443 761 (82%) individuals (dialysis or transplant recipients) begin-
ning ESRD therapy; 11 590 (2.6%) of these were transplants.
Predictors and outcomes
Additional data collected from Form 2728 included patient demo-
graphics, comorbid conditions, health insurance coverage and
recent (within 45 days) laboratory results. Mortality data were
identified via linkage with CROWNWeb (Consolidated Renal
Operations in a Web-enabled Network), the CMS Renal Manage-
ment Information System (REMIS) and CMS Form 2746 (ESRD
Death Notification). When multiple mortality dates were
recorded (n = 18), the median was used for analyses; most dif-
ferences were of just a few days. State of residence was as re-
ported at the time of ESRD onset; states were grouped by US
region (I–X), as defined by the CMS.
We chose to examine first-year mortality after the onset of
ESRD among dialysis patients because first-year mortality is par-
ticularly high and is most likely affected by pre-ESRD exposures
[17]. Outcome indicators of health and ESRD preparedness were
serum albumin >3.5 versus ≤3.5 g/dL, hemoglobin >11 versus
≤11 g/dL, choice of peritoneal dialysis (PD) versus hemodialysis
(HD) in dialysis patients, availability of a mature graft or fistula
versus catheter and whether informed of transplant options
versus not informed among dialysis patients.
Statistical methods
Separate analyses were conducted with each of the following
types of outcomes: (i) indicators of health and ESRD prepared-
ness at the start of ESRD (data from 2006 to 10) and (ii) mortality
in the first year of dialysis at both the individual and state levels
(data from 2007 to 10).
All indicators of health and ESRD preparedness outcomes,
dichotomized into more versus less desirable categories, were
assessed for their association with the duration of pre-ESRD
care (four categories) using logistic regression. In addition to
the duration of pre-ESRD care, other covariates included in the
models were age, gender, race, ethnicity, body mass index (BMI)
at ESRD incidence, diabetes as the primary cause of ESRD, co-
morbidities at incidence (congestive heart failure, atherosclerotic
heart disease, cerebrovascular disease, other cardiac diseases,
chronic obstructive pulmonary disease, peripheral vascular dis-
ease, diabetes, cancer, tobacco use, alcohol dependence, drug
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dependence, inability to ambulate and inability to transfer),
nursing home status and year of incidence. Associations of the
duration of pre-ESRD care with each of these outcome indicators
are presented as adjusted odds ratios (ORs) and 95% confidence
intervals (CIs).
Time to death within the first year of dialysis was modeled
using Cox regression censored at the earlier of transplant or
Day 365 since first dialysis. The duration of pre-ESRD care was
the exposure of primary interest, with adjustment for the same
covariates listed in the previous paragraph. Unadjusted and par-
tially adjusted models were also fit to assess possible confound-
ing. Hazard ratios (HRs) and 95% CIs are presented. For some
analyses, states were grouped by region (I–X) as defined by the
CMS.
In addition to the individual-level analyses described above, a
state-level ecologic analysis was performed in the dialysis popu-
lation to assess the association between the proportion of
patients with >12 months of pre-ESRD nephrology care and
first-year mortality, where both the predictor and outcome
were adjusted for the same covariates (age, sex, race, ethnicity,
diabetes, nursing home status, BMI and comorbidities at ESRD
onset and state age-adjusted race-specific death rate). The out-
come was the average of the 2007–9 year-specific standardized
mortality ratios (SMRs) for each state compared with the US
dialysis population. These SMRs were obtained from the CMS
Dialysis Facility Reports Technical Notes on the Standardized Mortal-
ity Ratio for the Dialysis Facility Reports [18]. The predictor was the
estimated proportion of new ESRD patients in each state with
>12 months of pre-ESRD nephrology care, standardized for the
same covariates as the SMR (except the state death rate). Each
standardized proportion was obtained by using logistic regres-
sion to estimate the predicted probability of >12 months pre-
ESRD nephrology care for each patient, then averaging those
probabilities across all patients in the state. Linear regression
was used to estimate the ecologic association between the
standardized proportion of patients with >12 months pre-ESRD
nephrology care and the SMR. Data were analyzed using SAS
9.3 (SAS Institute, Cary, NC, USA).
Results
Of the 443 761 incident cases of ESRD in the USA included in this
study, 33% had received no nephrology care prior to ESRD onset,
14% had received <6 months, 25% had received ≥6 but ≤12
months and 28% had received >12 months of care prior to ESRD
onset (Table 1). Almost half (49%) were ≥65 years of age, 38%
were age 45–64 and <1% were of ≤18 years of age. Diabetes was
listed as the primary cause of ESRD for 59% of these individuals,
86%hadhypertension, 7%had no health insurance and <1%were
nursing home residents.
Any nephrology care prior to ESRD onset (versus no care) was
associatedwith better health status andpreparedness at the start
of ESRD (Table 2). In these adjusted analyses, pre-ESRD nephrol-
ogy care was positively associated with initial serum albumin
>3.5 g/dL, hemoglobin >11 g/dL and having been informed of
transplant options. Pre-ESRD nephrology care was strongly and
positively associated with initial PD versus HD [OR for >12
months versus no care = 5.50 (95% CI 5.29–5.73)] and initial graft
or fistula versus catheter access [OR = 11.3 (95% CI 11.0–11.5)].
Although not formally analyzed due to small numbers, pre-
emptive transplants were received by only three patients who
had no pre-ESRD nephrology care, but by 13, 15 and 47 patients
who had <6, 6–12 and >12 months of pre-ESRD nephrology care,
respectively.
Therewas an inverse dose–response association between the
duration of pre-ESRD nephrology care and the mortality rate
in the year after dialysis onset (Figure 1). Compared with
patients with no prior nephrology care, the adjusted HR was
0.73 (95% CI 0.71–0.74) for patients with <6 months of care, 0.72
(95% CI 0.70–0.73) for patients with 6–12 months of care and
0.58 (95% CI 0.57–0.59) for patients with >12 months of care.
Figure 2 shows the ecologic association between the standar-
dized proportion of new ESRD patients with >12 months of
pre-ESRD nephrology care (X-axis) and the SMR for first-year
mortality (Y-axis) among all US states. States with a 10% higher
standardized proportion of patients receiving >12 months of pre-
ESRD care had, on average, a 9.3% lower SMR (R2 = 0.47; P < 0.001).
Figure 3 summarizes adjusted associations between patient
characteristics and >12 months of pre-ESRD nephrology care
versus no care. The strongest predictor of this outcome was
insurance status [OR for insured versus uninsured = 3.6 (95% CI
3.5–3.8)]. There was also a positive monotonic association
between BMI and the duration of pre-ESRD nephrology care.
Other groups with more pre-ESRD care included age <18 years
(versus older) and hypertension (versus no comorbidity listed
in Figure 3). More than 12 months of pre-ESRD care was less fre-
quent in African Americans and Native Americans (versus
whites) and Hispanics (versus non-Hispanics). Therewas consid-
erable variability in pre-ESRD nephrology care across the nine
CMS regions. More than 12 months of pre-ESRD care was most
common in Regions I (New England states), X (Alaska, Idaho, Ore-
gon, Washington) and VIII (Colorado, Montana, North Dakota,
South Dakota, Utah, Wyoming).
Discussion
Although a number of studies have examined the link between
pre-ESRD care and patient outcomes after ESRD onset, this is
not only the largest study of its kind to date, including >400 000
incident ESRD patients throughout the USA during a recent
5-year period (2006–10), but it is also unique in that it reports
the results of an analysis at the state level. Results indicate that
US states that demonstrate a greater proportion of patients re-
ceiving longer nephrology care prior to ESRD have lower SMRs
at their dialysis facilities. While this result may simply be due
to the contextual effects of living in a state that has other fac-
tors/policies that improve access to care or health status, it raises
the possibility that if states/regions were to make concerted pol-
icy efforts to ensure a longer duration of pre-ESRD nephrology
care, themortality rates at their dialysis facilities could potential-
ly improve.
Consistent with previous reports frommany smaller US stud-
ies [4–14], as well as international studies [19–23], our results in-
dicate that a longer duration of pre-ESRD nephrology care is
associated with both better patient readiness for ESRD and great-
er 1-year survival after the start of dialysis. Patients receiving at
least 12 months of nephrology care were more likely to be better
informed of their ESRD options including PD and transplant,
more likely to have a preemptive transplant or have a functional
graft or fistula in place for dialysis, have more favorable labora-
tory values at the start of ESRD and have a higher probability of
surviving the critical first year of dialysis treatment. In spite of
these benefits, one-third of new ESRD patients were found to
have had no pre-ESRD nephrology care, and such care varied ap-
preciably across US regions. Many who initiated ESRD therapy
were from expected high-risk populations (i.e. older, diagnosed
with diabetes and/or hypertension, with disproportionate re-
presentation of minorities). However, nearly half of this incident
774 | B.W. Gillespie et al.
C
L
IN
IC
A
L
K
ID
N
E
Y
JO
U
R
N
A
L
Table 1. Frequency distribution (row percents) of prior duration of nephrology care among all incident ESRD patients (2006–10) in the USA
by selected variables
Overall
Duration of nephrology carea
No care <6 months 6–12 months >12 months
100% (n = 443 761) 33% (n = 147 746) 14% (n = 61 086) 25% (n = 110 339) 28% (n = 124 590)
Year
2006 88 186 33.4 12.6 27.7 26.3
2007 87 366 33.9 12.3 26.7 27.1
2008 87 897 33.6 13.6 24.3 28.5
2009 90 129 33.0 14.9 23.4 28.7
2010 90 183 32.6 15.5 22.3 29.6
Age (years)
<18 3472 30.1 17.6 21.2 31.2
18–44 53 960 41.5 12.5 23.5 22.6
45–64 168 731 34.8 13.4 25.3 26.6
65–74 104 276 29.6 14.1 25.6 30.7
≥75 113 322 30.7 14.5 24.3 30.5
Sex
Female 195 943 32.7 13.8 25.2 28.3
Male 247 818 33.8 13.8 24.6 27.9
Race
White 290 578 31.4 13.9 24.8 29.9
African American 127 243 37.8 13.2 24.7 24.3
Asian 18 944 31.4 15.7 26.3 26.6
Native American 4943 35.9 11.5 26.2 26.3
Others 2053 37.2 12.4 23.7 26.7
Ethnicity
Hispanic 59 521 40.4 10.7 26.8 22.0
Non-Hispanic 382 240 32.2 14.2 24.6 29.0
BMI (kg/m2)
<15 2136 38.2 17.0 23.3 21.6
15–19 32 041 39.6 13.3 23.7 23.5
20–24 115 583 35.9 13.5 24.4 26.2
25–29 124 150 32.8 13.9 24.9 28.5
≥30 165 668 30.6 13.9 25.4 30.2
Primary cause of ESRD
Diabetes 262 499 31.0 14.0 26.6 28.4
Other 181 262 36.7 13.4 22.3 27.7
Other comorbidity
Hypertension 382 399 32.1 13.5 25.2 29.2
Cardiac failure 147 019 34.4 13.3 24.8 27.5
ASHD 98 165 29.1 13.1 25.1 32.8
CVA 42 924 32.9 12.6 25.0 29.5
COPD 40 503 34.6 13.0 23.6 28.8
Cancer 32 910 34.3 12.7 22.6 30.4
Health insurance
Any 411 589 31.2 14.2 25.4 29.3
None 32 172 59.7 8.8 18.5 13.0
Nursing home
Resident 209 31.6 16.3 22.0 30.1
Nonresident 443 552 33.3 13.8 24.9 28.1
Region of residenceb
I 15 562 20.6 8.1 29.2 42.2
II 49 465 37.5 8.4 26.1 28.1
III 46 445 31.7 20.4 22.2 25.7
IV 98 738 32.9 15.1 23.8 28.2
V 72 560 32.0 17.1 21.8 29.1
VI 59 740 39.0 4.4 28.9 27.7
VII 17 638 31.1 12.5 23.2 33.2
VIII 9109 29.5 11.9 23.5 35.0
IX 61 289 33.7 19.4 26.8 20.2
Continued
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population was <65 years of age, a third were of normal or low
BMI and nearly 10% were uninsured, all factors that may make
them less likely to be identified by the healthcare system or to
see a nephrologist for care.
Results linking individual-level nephrologist care and patient
survival during the first year of dialysis were also seen at the state
level, even when adjusting for individual patient characteristics.
Table 1. Continued
Overall
Duration of nephrology carea
No care <6 months 6–12 months >12 months
100% (n = 443 761) 33% (n = 147 746) 14% (n = 61 086) 25% (n = 110 339) 28% (n = 124 590)
X 13 079 26.0 8.1 25.6 40.3
ASHD, atherosclerotic heart disease; BMI, body mass index; CVA, cerebrovascular atherosclerosis; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal
disease.
aDuration of nephrology care prior to ESRD onset as reported on CMS Form 2728.
bRegions are as follows—I: CT,MA,ME,NH, RI andVT; II: NJ, NY, VI and PR; III: DE,MD, PA,VA,WVandDC; IV: AL, FL, GA, KY,MS,NC, SC andTN;V: IL, IN,MI,MN,OHandWI;
VI: AR, LA, NM, OK, TX; VII: IA, KS, MO and NE; VIII: CO, MT, ND, SD, UT andWY; IX: AZ, CA, HI, NV, AS, GU andMP; X: AK, ID, OR andWA. For state abbreviations andmap,
see http://www.stateabbreviations.us.
Table 2. Adjusteda odds ratios (95% confidence intervals) for health and end stage renal disease (ESRD) preparedness at the time of ESRD, by
duration of nephrology care (<6, 6–12 and >12 months versus no care)
Outcome No care <6 months 6–12 months >12 months
Favorable laboratory values
Albumin >3.5 versus ≤3.5 g/dL 1 1.96 (1.91, 2.00) 1.91 (1.88, 1.95) 2.50 (2.45, 2.54)
Hemoglobin >11 versus ≤11 g/dL 1 1.54 (1.51, 1.58) 1.51 (1.48, 1.54) 1.76 (1.73, 1.80)
Optimal dialysis methods
Starting with peritoneal or other versus hemodialysis 1 4.57 (4.37, 4.78) 4.23 (4.06, 4.41) 5.51 (5.29, 5.73)
First vascular access with graft or fistula versus catheter 1 6.77 (6.59, 6.96) 6.45 (6.29, 6.62) 11.26 (10.99, 11.53)
Access to transplantation
Informed of transplantation option versus not informed 1 1.43 (1.39, 1.46) 1.39 (1.36, 1.41) 1.51 (1.49, 1.54)
Number of patients: total n = 147 746 n = 61 086 n = 110 339 n = 124 590
Albumin >3.5 g/dL n = 63 624 n = 32 782 n = 57 148 n = 71 450
Hemoglobin >11 g/dL n = 39 520 n = 20 674 n = 36 715 n = 45,934
Starting with peritoneal or other dialysis type n = 3454 n = 5857 n = 9431 n = 13 784
First access with graft or fistula n = 9240 n = 19 232 n = 32 941 n = 53 234
Informed of transplant options n = 43 846 n = 14 317 n = 26 547 n = 28 600
aAdjusted for age, gender, race, ethnicity, insurance status, bodymass index, diabetes as acause of ESRD, comorbidities, year of incidence andnursing home residence. For
all odds ratios presented, P-values were <0.0001.
Fig. 1. Adjusted hazard ratios (and 95% confidence intervals) for mortality during
the first year of dialysis, by duration of pre-ESRDnephrology care (<6, 6–12 and >12
months versus no care). Models were adjusted for age, gender, race, ethnicity,
insurance, body mass index, diabetes as a cause of ESRD, comorbidities, year of
incidence and nursing home residence. ESRD, end stage renal disease; Ref,
reference category.
Fig. 2. First-year state-specific standardized mortality ratio (SMR) by adjusted
state-specific probability of >12 months of pre-ESRD nephrology care among US
dialysis patients, 2007–10. The fitted regression line (Y^ ¼ 1:22 0:93X; R2 = 0.47,
P < 0.001) is given with pointwise 95% confidence intervals. Each state SMR is
based on an adjusted comparison of first-year mortality in the dialysis
populations of that state versus the USA, standardized to the US mean
covariate values. Both the SMR and proportion with >12 months of pre-ESRD
nephrology care were adjusted for the same covariates: patient’s age, sex, race,
ethnicity, body mass index, comorbidities at incidence, diabetes as the listed
cause of ESRD, duration of ESRD, nursing home status and population death
rates (SMR only). ESRD, end stage renal disease.
776 | B.W. Gillespie et al.
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Fig. 3.Adjusted1 OR (95% CI) for >12months of pre-ESRD nephrology care versus no care by category of selected covariates. ASHD, atherosclerotic heart disease; BMI, body
mass index; CI, confidence interval; CMS, Centers forMedicare andMedicaid Services; CVA, cerebrovascular atherosclerosis; COPD, chronic obstructive pulmonarydisease;
ESRD, end-stage renal disease; OR, odds ratio. 1Adjusted for age, sex, race, ethnicity, BMI, diabetes as a cause of ESRD, comorbidities (hypertension, cardiac failure, ASHD,
CVA, COPD, cancer), insurance status, nursing home residence, year of incidence and CMS region. Regions are as follows—I: CT,MA,ME, NH, RI andVT; II: NJ, NY, VI and PR;
III: DE,MD, PA, VA,WVandDC; IV: AL, FL, GA, KY,MS, NC, SC andTN;V: IL, IN,MI,MN,OHandWI; VI: AR, LA, NM,OKandTX; VII: IA, KS,MOandNE; VIII: CO,MT,ND, SD, UT
and WY; IX: AZ, CA, HI, NV, AS, GU and MP; X: AK, ID, OR and WA. For state abbreviations, see http://www.stateabbreviations.us.
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These results may reflect the contextual effect of living in a state
with more nephrology care, controlling for individual pre-ESRD
nephrology-care status. Alternatively, they may reflect the indi-
vidual-level effect of receiving nephrology care earlier in the
course of CKD (as suggested by our findings in Figure 1) or ecolo-
gic bias resulting from missing data in the state-level analysis;
those two effects are confounded in our ecologic analysis [24].
Furthermore, the ecologic findings may also be confounded by
unmeasured patient-level or state-level factors such as health-
care policies or programs affecting population awareness and ac-
cess. Given the strong association we observed between health
insurance coverage and longer duration of pre-ESRD nephrology
care, we might expect the Affordable Care Act to have a notice-
able impact on CKD nephrology care and early ESRD mortality.
Results presented here show that themajority of US ESRD pa-
tients do not receive at least 12 months of pre-ESRD care, with
wide variation in the length of care across the country. Although
12months of pre-ESRD carewas found to be optimal in our study,
Bradbury et al. [25] found that any predialysis nephrology care im-
proved postdialysis mortality, with the greatest benefit found
during the first 4 months of dialysis. Barriers to pre-ESRD care
arise from a variety of sources, with a major factor being health-
care access. As our results show, pre-ESRD carewas related to pa-
tient characteristics, including demographics, insurance status
and health indicators. These results are consistent with the find-
ings of McClellan et al. [15], who emphasized patients’ socio-
economic status as a major predictor of access to nephrology
care, and related geographic variation in care to zip codes of resi-
dence associated with poverty. Crews et al. [26] found that low
socioeconomic status was associated with a much larger associ-
ationwith kidney disease in AfricanAmericans than inwhites. In
addition, there is a growing body of literature detailing, at both
the individual and healthcare-system levels, a lack of awareness
of declining kidney function [27–30]. National Institutes of
Health-based initiatives, such as the National Kidney Disease
Education Program, aim to increase awareness of CKD at both
the patient and provider levels, whichmay lead to corresponding
increases in nephrologist care [31]. Another potential barrier to
care is the availability of practicing nephrologists to meet the
needs of a growing populationwith CKD [32, 33]. Delay of primary
care physicians in referring patients to nephrologists represents
another barrier to optimization of care [34] thatmight explain the
significant proportion of ‘acute’ discoveries of ESRD. Advance-
ments in healthcare information technology [e.g. computer-
based decision support systems and automated reporting of
estimated glomerular filtration rate (eGFR)], as well as the
development of organized CKD clinics and CKD registries, may
alleviate some of these deficiencies by reminding clinicians
from both primary and specialty care to test, manage and appro-
priately refer individuals with established kidney disease as well
as thosewith identified kidney disease risk factors [35, 36]. In this
context, research into system changes that could reduce barriers
to nephrology care, improve patient outcomes and reduce health
disparities is needed.
Limitations of this study include a lack of data to adjust for
potential confounders such as a patient’s socioeconomic status,
social support network, awareness of disease, general access to
care, symptom severity or prior rate of CKDprogression. A second
limitation is that ‘<6 months’ on the Form 2728 question on the
duration of pre-ESRD care could only be selected by nonendorse-
ment of the other two categories; this choice was indistinguish-
able from nonendorsement because the duration of nephrologist
care was unknown, possibly leading to misclassification. A third
limitation is the nonavailability of a patient’s eGFR at their first
nephrology visit, as internationally recognized guidelines such
as those from the KDOQI and Kidney Disease: Improving Global
Outcomes base nephrology referral on a patient’s eGFR or CKD
stage. Similarly, the number and quality of nephrology visits
within the indicated duration of carewere unavailable. This add-
itional information could be addressed prospectively by ongoing
studies such as the Chronic Renal Insufficiency Cohort study [37].
Perhaps themajor limitation of this study is that the study popu-
lation was restricted to new ESRD patients. Thus, it does not
allow us to directly address the fundamental question of interest
for guiding clinical practice: at what point in the course of CKD
should individuals initiate nephrology care? Recommending
referral at least 12 months before ESRD requires inaccessible
knowledge of the future. To address this fundamental clinical
question, wewould need to follow patientswith CKD from earlier
stages to the start of ESRD or death, using an observational or
randomized design.
Because the duration of pre-ESRD nephrology care from the
Medical Evidence Report (Form 2728) is not strongly correlated
with that variable from Medicare claims [38], we recognize that
our variable is likely measured with error, which could have
biased our results. The direction of such bias, however, would
probably be toward the null value of HR = 1, unless the amount
of misclassification was strongly and monotonically associated
with mortality, conditional on measured covariates, which
seems unlikely. Thus, the strong associations we observed were
not likely due to misclassification bias. Furthermore, our esti-
mates of the relative hazard of mortality with and without
prior nephrology care are consistent with those of Bradbury
et al. [25].
In conclusion, we found that a large proportion of new ESRD
patients in the USA had not received pre-ESRD nephrology care,
and the average duration of such care varied widely across the
country. Our findings suggest that early nephrology care of CKD
patients may, if the disease progresses to ESRD, reduce first-
year mortality after ESRD onset, presumably by improving the
patient’s health and readiness for renal replacement therapy.
Our state-level analysis suggests significant variation in this pat-
tern of care among US states and indicates the potential benefits
of policy-driven, earlier CKD care for ESRD patients living in
regions with lower rates and with longer duration nephrology
care. In this context, the proportion of CKD patients receiving
timely nephrology care is likely to improvewith greater availabil-
ity of health insurance under the Affordable Care Act, whichmay
yield health benefits to persons with CKD/ESRD through im-
proved access to care as well as general health promotion efforts.
The Department of Health and Human Services’ Healthy
People 2010 (HP2010) objectives to improve pre-ESRD care
(particularly nephrology referral and arteriovenous fistula place-
ment) have been retained in the proposed HP2020 objectives [39].
These national objectives, as well as the ongoing multipronged
response to CKD that US federal agencies have developed [40],
should continue to help policymakers focus efforts and allocate
resources appropriately. The results provided here should stimu-
late thoughtful discussion on developing public health strategies
to encourage earlier referral to a nephrologist among all socio-
economic groups. Such strategies have the potential to improve
outcomes for those with CKD and ESRD.
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